mcd003

Marinos C. Dalakas, MD, FAAN

Contact Dr. Dalakas

901 Walnut Street
4th Floor
Philadelphia, PA 19107

(215) 955 -7865
(215) 955-9976 fax

Most Recent Peer-reviewed Publications

  1. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome
  2. Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors
  3. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome
  4. Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease
  5. Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis
  6. Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business
  7. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
  8. Close to the node but far enough
  9. Viruses in IBM: Hit-and-run, hide and persist, or irrelevant?
  10. The spectrum of inflammatory myopathies: Dermatomyositis, polymyositis, necrotizing myositis, and inclusion-body myositis
  11. Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future
  12. Necrotising autoimmune myopathy (NAM): Antibodies seem to be specific markers in aiding diagnosis
  13. Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity
  14. Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials
  15. Efficacy of Intravenous Immunoglobulin in Neurological Diseases
  16. Progressive encephalomyelitis with rigidity and myoclonus (PERM): Brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab
  17. Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease
  18. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity
  19. Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4
  20. Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse